JP2019500345A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500345A5
JP2019500345A5 JP2018529229A JP2018529229A JP2019500345A5 JP 2019500345 A5 JP2019500345 A5 JP 2019500345A5 JP 2018529229 A JP2018529229 A JP 2018529229A JP 2018529229 A JP2018529229 A JP 2018529229A JP 2019500345 A5 JP2019500345 A5 JP 2019500345A5
Authority
JP
Japan
Prior art keywords
seq
mrna
protein
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018529229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/066564 external-priority patent/WO2017106283A1/en
Publication of JP2019500345A publication Critical patent/JP2019500345A/ja
Publication of JP2019500345A5 publication Critical patent/JP2019500345A5/ja
Pending legal-status Critical Current

Links

JP2018529229A 2015-12-14 2016-12-14 肝臓病の処置のための組成物および方法 Pending JP2019500345A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562267238P 2015-12-14 2015-12-14
US62/267,238 2015-12-14
US201662319015P 2016-04-06 2016-04-06
US62/319,015 2016-04-06
PCT/US2016/066564 WO2017106283A1 (en) 2015-12-14 2016-12-14 Compositions and methods for treatment of liver diseases

Publications (2)

Publication Number Publication Date
JP2019500345A JP2019500345A (ja) 2019-01-10
JP2019500345A5 true JP2019500345A5 (https=) 2020-01-30

Family

ID=59057460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529229A Pending JP2019500345A (ja) 2015-12-14 2016-12-14 肝臓病の処置のための組成物および方法

Country Status (4)

Country Link
EP (1) EP3389672A4 (https=)
JP (1) JP2019500345A (https=)
CA (1) CA3005090A1 (https=)
WO (1) WO2017106283A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
EP3359685B1 (en) 2015-10-09 2026-01-28 University Of Southampton Modulation of gene expression for deregulated protein expression
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
EP3461837A1 (en) * 2017-09-28 2019-04-03 Secarna Pharmaceuticals GmbH & Co. KG Inhibitor inhibiting the expression of pprx1
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
GB2610100B (en) 2017-10-23 2023-08-16 Stoke Therapeutics Inc Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
CN112041439A (zh) * 2018-02-14 2020-12-04 深度基因组学公司 用于威尔森病的寡核苷酸疗法
KR20200140805A (ko) * 2018-02-21 2020-12-16 브리스톨-마이어스 스큅 컴퍼니 Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
TWI856973B (zh) * 2018-09-19 2024-10-01 美商Ionis製藥公司 Pnpla3表現之調節劑
US10913951B2 (en) * 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
CN111849968A (zh) * 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
EP4017979A4 (en) * 2019-08-19 2024-03-27 Stoke Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING PROTEIN SPLICING AND EXPRESSION
US20230212565A1 (en) * 2019-09-20 2023-07-06 Ractigen Therapeutics Nucleic acid molecule for treating thrombocytopenia and application thereof
EP4045062A1 (en) * 2019-10-14 2022-08-24 Astrazeneca AB Modulators of pnpla3 expression
WO2021113773A2 (en) 2019-12-04 2021-06-10 Pai Athma A Identifying non-productive splice sites
TWI817107B (zh) * 2020-04-15 2023-10-01 中央研究院 寡核苷酸共軛物及其製備與應用
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
EP4150078A1 (en) * 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2022018187A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Oligonucleotides targeting rna binding protein sites
WO2022109030A1 (en) * 2020-11-17 2022-05-27 Skyhawk Therapeutics, Inc. Rna-targeting splicing modifiers for treatment of pnpla3-associated conditions and diseases
WO2025226980A2 (en) * 2024-04-25 2025-10-30 Insitro, Inc. Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0669987B1 (en) 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
US6936589B2 (en) 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
JP5202296B2 (ja) * 2005-04-01 2013-06-05 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 肝臓傷害のバイオマーカー
WO2007047913A2 (en) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
PT3305302T (pt) 2009-06-17 2018-12-14 Biogen Ma Inc Composições e métodos de modulação de excisões de smn2 em um sujeito
WO2012075040A2 (en) * 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US20140128449A1 (en) * 2011-04-07 2014-05-08 The Board Of Regents Of The University Of Texas System Oligonucleotide modulation of splicing
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
PL3041958T4 (pl) 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi

Similar Documents

Publication Publication Date Title
JP2019500345A5 (https=)
AU2016200344B2 (en) Compositions and methods for modulation of smn2 splicing in a subject
JP7049247B2 (ja) 腎臓病の処置のための組成物と方法
JP6006120B2 (ja) 対立遺伝子多様体の選択的低減
JP6018506B2 (ja) 対立遺伝子多様体の選択的低減
CN103038349B (zh) 调节通过miR-378实现的代谢
JP2019501892A5 (https=)
JP7054675B2 (ja) 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法
US20120149757A1 (en) Compositions and methods for modulation of smn2 splicing
KR20080031164A (ko) ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
US20200181613A1 (en) Compositions and methods for modulation of smn2 splicing
JP2019500346A5 (https=)
JP2019500345A (ja) 肝臓病の処置のための組成物および方法
JP2018538288A5 (https=)
JP2011513238A (ja) 平滑筋の増殖および分化を調節するマイクロｒｎａならびにこれらの使用
CN116209761A (zh) 靶向rna结合蛋白位点的寡核苷酸
JP2018538287A5 (https=)
KR20230047453A (ko) 대사 증후군 치료를 위한 조성물 및 방법
JP2018538287A (ja) 多発性嚢胞腎の処置のためのアンチセンスオリゴマー
Gibson Engineered microRNA therapeutics
Lim et al. Genetic approaches for the treatment of facioscapulohumeral muscular dystrophy
Ho et al. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS
Latronico et al. Therapeutic applications of noncoding RNAs
WO2025103391A1 (zh) 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
Bischof et al. Exploiting the hypoxia sensitive non-coding genome for organ-specific physiologic reprogramming